Effects of Azelastine on Glioblastoma Cells
AZL inhibits glioblastoma cell growth primarily through G<sub>1</sub> arrest and cytoskeletal remodeling, with minimal contribution from classical cell death pathways. Its ability to enhance TMZ and DOX efficacy, coupled with favorable BBB permeability and low toxicity, supports its potential as a repositioned therapeutic for glioblastoma, both as a monotherapy and as an adjuvant to overcome TMZ resistance.
Authors
- Miyuki Mabuchi
- Shuji Nagano (ORCID: https://orcid.org/0009-0004-6844-4801)
- Tadashi Shimizu (ORCID: https://orcid.org/0000-0002-5563-6730)
- Yuki Uemichi
- Seina Yasuda
- S Nakao
Institutions
- Hyogo University (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-06-27
- DOI
- https://doi.org/10.21873/anticanres.17645
- Primary Topic
- Synthesis and biological activity
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science